|
1
|
Chua MLK, Wee JTS, Hui EP and Chan ATC:
Nasopharyngeal carcinoma. Lancet. 387:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee AW, Ma BB, Ng WT and Chan AT:
Management of nasopharyngeal carcinoma: Current practice and future
perspective. J Clin Oncol. 33:3356–3364. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang J, Samuels DC, Zhao S, Xiang Y, Zhao
YY and Guo Y: Current research on non-coding ribonucleic acid
(RNA). Genes. 8:E3662017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peng XH, Huang HR, Lu J, Liu X, Zhao FP,
Zhang B, Lin SX, Wang L, Chen HH, Xu X, et al: MiR-124 suppresses
tumor growth and metastasis by targeting Foxq1 in nasopharyngeal
carcinoma. Mol Cancer. 13:1862014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Y, Li Z, Wu L, Wang Z, Wang X, Yu Y,
Zhao Q and Luo F: MiRNA-125a-5p: A regulator and predictor of
gefitinib's effect on nasopharyngeal carcinoma. Cancer Cell Int.
14:242014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu RS, Qiu EH, Zhu JJ, Wang JR and Lin HL:
MiR-101 promotes nasopharyngeal carcinoma cell apoptosis through
inhibiting Ras/Raf/MEK/ERK signaling pathway. Eur Rev Med Pharmacol
Sci. 22:150–157. 2018.PubMed/NCBI
|
|
8
|
Xia H, Ng SS, Jiang S, Cheung WK, Sze J,
Bian XW, Kung HF and Lin MC: miR-200a-mediated downregulation of
ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma
cell growth, migration and invasion. Biochem Biophys Res Commun.
391:535–541. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang X, Ni W and Lei K: miR-200b
suppresses cell growth, migration and invasion by targeting notch1
in nasopharyngeal carcinoma. Cell Physiol Biochem. 32:1288–1298.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shao Q, Zhang P, Ma Y, Lu Z, Meng J, Li H,
Wang X, Chen D, Zhang M, Han Y, et al: MicroRNA-139-5p affects
cisplatin sensitivity in human nasopharyngeal carcinoma cells by
regulating the epithelial-to-mesenchymal transition. Gene.
652:48–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao M, Luo R, Liu Y, Gao L, Fu Z, Fu Q,
Luo X, Chen Y, Deng X, Liang Z, et al: miR-3188 regulates
nasopharyngeal carcinoma proliferation and chemosensitivity through
a FOXO1-modulated positive feedback loop with
mTOR-p-PI3K/AKT-c-JUN. Nat Commun. 7:113092016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang JX, Qian D, Wang FW, Liao DZ, Wei
JH, Tong ZT, Fu J, Huang XX, Liao YJ, Deng HX, et al: MicroRNA-29c
enhances the sensitivities of human nasopharyngeal carcinoma to
cisplatin-based chemotherapy and radiotherapy. Cancer Lett.
329:91–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma F, Wang Z, Wang J, Liu X and Hu C:
MicroRNA-19a promotes nasopharyngeal carcinoma by targeting
transforming growth factor β receptor 2. Exp Ther Med.
14:1419–1426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu W, Chen X, Yu S, Wang R, Zhao R and Du
C: microRNA-222 promotes tumor growth and confers radioresistance
in nasopharyngeal carcinoma by targeting PTEN. Mol Med Rep.
17:1305–1310. 2018.PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arias-Romero LE and Chernoff J: Targeting
Cdc42 in cancer. Expert Opin Ther Targets. 17:1263–1273. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Krause M, Dent EW, Bear JE, Loureiro JJ
and Gertler FB: Ena/VASP proteins: Regulators of the actin
cytoskeleton and cell migration. Annu Rev Cell Dev Biol.
19:541–564. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grady WM, Parkin RK, Mitchell PS, Lee JH,
Kim YH, Tsuchiya KD, Washington MK, Paraskeva C, Willson JK, Kaz
AM, et al: Epigenetic silencing of the intronic microRNA
hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene.
27:3880–3888. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao L and Zhang Y: miR-342-3p affects
hepatocellular carcinoma cell proliferation via regulating NF-κB
pathway. Biochem Biophys Res Commun. 457:370–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li XR, Chu HJ, Lv T, Wang L, Kong SF and
Dai SZ: miR-342-3p suppresses proliferation, migration and invasion
by targeting FOXM1 in human cervical cancer. FEBS Lett.
588:3298–3307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang S, Liu L, Lv Z, Li Q, Gong W and Wu
H: MicroRNA-342-3p inhibits the proliferation, migration, and
invasion of osteosarcoma cells by targeting astrocyte-elevated
gene-1 (AEG-1). Oncol Res. 25:1505–1515. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang H, Fan L, Zhan R, Wu S and Niu W:
Expression of microRNA-10a, microRNA-342-3p and their predicted
target gene TIAM1 in extranodal NK/T-cell lymphoma, nasal type.
Oncol Lett. 11:345–351. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cittelly DM, Das PM, Spoelstra NS,
Edgerton SM, Richer JK, Thor AD and Jones FE: Downregulation of
miR-342 is associated with tamoxifen resistant breast tumors. Mol
Cancer. 9:3172010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xue X, Fei X, Hou W, Zhang Y, Liu L and Hu
R: miR-342-3p suppresses cell proliferation and migration by
targeting AGR2 in non-small cell lung cancer. Cancer Lett.
412:170–178. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang H, Wu J, Meng X, Ying X, Zuo Y, Liu
R, Pan Z, Kang T and Huang W: MicroRNA-342 inhibits colorectal
cancer cell proliferation and invasion by directly targeting DNA
methyltransferase 1. Carcinogenesis. 32:1033–1042. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu HP, Chen CC, Wu CC, Huang YC, Liu SC,
Liang Y, Chang KP and Chang YS: Epstein-Barr virus-encoded LMP1
interacts with FGD4 to activate Cdc42 and thereby promote migration
of nasopharyngeal carcinoma cells. PLoS Pathog. 8:e10026902012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsang CM, Lau EP, Di K, Cheung PY, Hau PM,
Ching YP, Wong YC, Cheung AL, Wan TS, Tong Y, et al: Berberine
inhibits Rho GTPases and cell migration at low doses but induces G2
arrest and apoptosis at high doses in human cancer cells. Int J Mol
Med. 24:131–138. 2009.PubMed/NCBI
|
|
28
|
Bradshaw-Pierce EL, Pitts TM, Tan AC,
McPhillips K, West M, Gustafson DL, Halsey C, Nguyen L, Lee NV, Kan
JL, et al: Tumor P-glycoprotein correlates with efficacy of
PF-3758309 in in vitro and in vivo models of colorectal cancer.
Front Pharmacol. 4:222013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pelish HE, Peterson JR, Salvarezza SB,
Rodriguez-Boulan E, Chen JL, Stamnes M, Macia E, Feng Y, Shair MD
and Kirchhausen T: Secramine inhibits Cdc42-dependent functions in
cells and Cdc42 activation in vitro. Nat Chem Biol. 2:39–46. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Murray BW, Guo C, Piraino J, Westwick JK,
Zhang C, Lamerdin J, Dagostino E, Knighton D, Loi C, Zager M, et
al: Small-molecule p21-activated kinase inhibitor PF-3758309 is a
potent inhibitor of oncogenic signaling and tumor growth. Proc Natl
Acad Sci USA. 107:9446–9451. 2010. View Article : Google Scholar : PubMed/NCBI
|
